Impact of Drug Manipulation on Seizure Freedom in Adults with Uncontrolled Epilepsy: A Prospective Controlled Study in Rural China
Introduction It has been suggested that uncontrolled epilepsy might not necessarily equate to drug resistance when antiepileptic drugs (AEDs) are used at relatively low doses, a practice frequently observed in rural areas of China. Objective To assess the clinical benefits of further drug manipulation in this situation, we prospectively followed up the outcomes of patients with uncontrolled epilepsy while taking relatively low doses of AEDs. Methods The study included patients aged 16 years and older with uncontrolled epilepsy and who were receiving at least one AED at a dosage below 50% of the World Health Organization (WHO) defined daily dose (DDD) (50% DDD) (Group 1). Patients with drug-resistant epilepsy were included for comparison (Group 2). Both groups were followed-up for at least 2 years. Seizure outcomes after further drug manipulations were recorded at the last follow-up. Results A total of 197 patients (55.3% male) were included in Group 1 and 32 (46.9% male) in Group 2; their mean duration of follow-up was 28.85 ± 1.90 and 30.91 ± 2.04 months, respectively. At the last follow-up, 16.8% (33/197) of patients in Group 1 had become seizure-free compared with none in Group 2 (p < 0.001). Seventeen of 93 (18.3%) patients in Group 1 became seizure free after increasing the dosage of baseline AED(s) alone. Only 5.5% (3/55) of patients who had failed to respond to an AED at ≥50% DDD at baseline became seizure free compared with 21.1% (30/142) who did not have such a history (p = 0.001). The number of AEDs taken at a dosage below 50% DDD at baseline was not associated with seizure outcome. Conclusions Uncontrolled epilepsy could become controlled in a substantial proportion of patients by dose increase alone, particularly if there is no history of drug failure at ≥50% DDD..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
CNS drugs - 31(2017), 3 vom: März, Seite 237-243 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hao, Xiaoting [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Define Daily Dose |
| RVK: |
|---|
| doi: |
10.1007/s40263-016-0397-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC203765944X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC203765944X | ||
| 003 | DE-627 | ||
| 005 | 20230507220445.0 | ||
| 007 | tu | ||
| 008 | 200819s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40263-016-0397-5 |2 doi | |
| 035 | |a (DE-627)OLC203765944X | ||
| 035 | |a (DE-He213)s40263-016-0397-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q AVZ |
| 084 | |a PHARM |2 fid | ||
| 084 | |a XA 37190 |q AVZ |2 rvk | ||
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.91 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Hao, Xiaoting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Drug Manipulation on Seizure Freedom in Adults with Uncontrolled Epilepsy: A Prospective Controlled Study in Rural China |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Introduction It has been suggested that uncontrolled epilepsy might not necessarily equate to drug resistance when antiepileptic drugs (AEDs) are used at relatively low doses, a practice frequently observed in rural areas of China. Objective To assess the clinical benefits of further drug manipulation in this situation, we prospectively followed up the outcomes of patients with uncontrolled epilepsy while taking relatively low doses of AEDs. Methods The study included patients aged 16 years and older with uncontrolled epilepsy and who were receiving at least one AED at a dosage below 50% of the World Health Organization (WHO) defined daily dose (DDD) (50% DDD) (Group 1). Patients with drug-resistant epilepsy were included for comparison (Group 2). Both groups were followed-up for at least 2 years. Seizure outcomes after further drug manipulations were recorded at the last follow-up. Results A total of 197 patients (55.3% male) were included in Group 1 and 32 (46.9% male) in Group 2; their mean duration of follow-up was 28.85 ± 1.90 and 30.91 ± 2.04 months, respectively. At the last follow-up, 16.8% (33/197) of patients in Group 1 had become seizure-free compared with none in Group 2 (p < 0.001). Seventeen of 93 (18.3%) patients in Group 1 became seizure free after increasing the dosage of baseline AED(s) alone. Only 5.5% (3/55) of patients who had failed to respond to an AED at ≥50% DDD at baseline became seizure free compared with 21.1% (30/142) who did not have such a history (p = 0.001). The number of AEDs taken at a dosage below 50% DDD at baseline was not associated with seizure outcome. Conclusions Uncontrolled epilepsy could become controlled in a substantial proportion of patients by dose increase alone, particularly if there is no history of drug failure at ≥50% DDD. | ||
| 650 | 4 | |a Oxcarbazepine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Define Daily Dose |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Seizure Outcome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Seizure Freedom |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a West China Hospital |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chen, Ziyi |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Kwan, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Dong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS drugs |d [Heidelberg] : Springer, 1994 |g 31(2017), 3 vom: März, Seite 237-243 |w (DE-627)182392813 |w (DE-600)1203800-3 |w (DE-576)043086012 |x 1172-7047 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2017 |g number:3 |g month:03 |g pages:237-243 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s40263-016-0397-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-PSY | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | r | v | |a XA 37190 |
| 936 | b | k | |a 44.40 |q AVZ |
| 936 | b | k | |a 44.91 |q AVZ |
| 936 | b | k | |a 44.38 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 31 |j 2017 |e 3 |c 03 |h 237-243 | ||